Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes by Escaned, J et al.
INCLUSION AND EXCLUSION CRITERIA 
 
Inclusion criteria 
 
DEFINE-FLAIR study 
 
1. Age > 18 years. 
2. Willing to participate and able to understand, read and sign the informed consent 
document before the planned procedure. 
3. Eligible for coronary angiography and/or percutaneous coronary intervention. 
4. Coronary artery disease in one or more native major epicardial vessels or their branches by 
coronary angiogram with visually assessed de novo coronary stenosis in which the 
physiological severity of the lesion is in question (typically 40-70% diameter stenosis). 
5. Stable angina or ACS (non-culprit vessels only and outside of primary intervention during 
acute STEMI). 
 
iFR-SWEDEHEART study 
 
1. Provision of informed consent prior to any study specific procedures. 
2. Patient must be ≥ 18 years old. 
3. Patients with suspected stable angina pectoris or unstable angina pectoris/NSTEMI who are 
scheduled to undergo coronary angiography, and where there is an indication for physiology 
guided assessment of coronary lesions (recommend assessment of lesions with a stenosis 
grade of 40-80%). 
4. In patients with suspected stable angina pectoris, any lesion may be assessed. In patients with 
unstable angina pectoris/NSTEMI only the non-culprit lesion may be assessed. 
 
 
Exclusion criteria 
 
DEFINE-FLAIR study 
 
1. Previous CABG with patent grafts to the interrogated vessel. 
2. Significant left main stenosis (>50% narrowing). 
3. Tandem stenoses separated by more than 10 mm that require separate pressure 
guide wire interrogation or PCI (not to be interrogated or treated as a single 
stenosis). 
4. Total coronary occlusions (CTOs). NOTE: Patients with CTOs can be included if i) 
treatment of the CTO is completed first ii) the CTO PCI is successful and iii) the 
physiological lesion is in another vessel. 
5. Restenotic lesions. 
6. Haemodynamic instability at the time of intervention (heart rate<50 beats per minute, 
systolic blood pressure <90mmHg), balloon pump. 
7. Significant contraindication to adenosine administration (e.g. heart block, severe asthma). 
8. Contraindications to PCI or drug-eluting stent (DES) implantation. 
9. Heavily calcified or tortuous vessels. 
10. Significant hepatic or lung disease (chronic pulmonary obstructive disease), and/or 
malignant disease with unfavourable prognosis that may influence survival within 
the next 5 years. 
11. Pregnancy. 
12. STEMI within 48 hours of procedure. 
13. Severe valvular heart disease. 
14. ACS patients in whom more than one target vessel is present. 
 
iFR-SWEDEHEART study 
 
1. Previous CABG with patent grafts to the interrogated vessel. 
2. Inability to provide informed consent. 
3. Previous randomization in the iFR-SWEDEHEART trial. 
4. Known terminal disease with a life expectancy of less than one year. 
5. In patients with multi-vessel disease and other indication than stable angina pectoris, 
difficulty in assessing which is the culprit lesion. 
6. Patient with unstable hemodynamics (Killip class III-IV). 
7. Inability to tolerate adenosine. 
8. Heavily calcified or tortuous vessels where inability to cross the lesion with a pressure wire 
is expected. 
 
 
 
  
SUPPLEMENTARY FIGURE LEGEND 
 
Figure 1: Cumulative risk of primary endpoint MACE by physiological technique in the overall 
population  
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Table 1. Baseline Characteristics of the overall population  
 
  iFR (N=2240) FFR (N=2246) 
Age (years) 66.5 ±10.3 66.2 ±10.1 
Male 76.0% (1703/2240) 74.8% (1680/2246) 
Body mass index (kg/m2) 27.7 ±4.7 27.5 ±4.7 
Diabetes mellitus 27.1% (606/2240) 26.0% (585/2246) 
Hypertension 70.9% (1589/2240) 70.4% (1582/2246) 
Hyperlipidaemia 67.6% (1514/2240) 66.0% (1482/2246) 
Current smoker 17.9% (400/2240) 18.8% (422/2246) 
Previous MI 30.8% (689/2240) 31.3% (703/2246) 
Previous PCI 40.6% (910/2240) 42.0% (943/2246) 
Clinical presentation   
Acute coronary syndrome 27.6% (619/2240) 26.7% (600/2246) 
Stable coronary disease 71.6% (1604/2240) 72.8% (1635/2246) 
No information 0.8% (17/2240) 0.5% (11/2246) 
iFR = instantaneous wave-free ratio, FFR= fractional flow reserve, MI = myocardial infarction, 
PCI = percutaneous coronary intervention.
Table 2. Outcomes in the overall population according to iFR or FFR. 
 
Outcome iFR (N=2240) FFR (N=2246) HR iFR vs FFR (95% CI) p-value 
MACE, % (n) 6.47% (145/2240) 6.41% (144/2246) 1.03 (0.81-1.31) 0.81 
All-cause death, % (n) 1.61% (36/2240) 1.11% (25/2246) 1.46 (0.88-2.44) 0.14 
Cardiovascular death, % (n) 0.67% (15/2240) 0.45% (10/2246) 1.52 (0.68-3.39) 0.30 
Non-cardiovascular death, % (n) 0.94% (21/2240) 0.67% (15/2246) 1.42 (0.73-2.76) 0.30 
Myocardial infarction, % (n) 2.37% (53/2240) 2.00% (45/2246) 1.19 (0.76-1.85) 0.45 
Unplanned revascularisation, % (n) 4.15% (93/2240) 4.85% (109/2246) 0.91 (0.69-1.21) 0.53 
 
HR denotes hazard ratio; MACE, major adverse cardiac events. Other abbreviations as in Table 1 
 
Table 3: Outcomes in the overall population according to clinical presentation (SAP vs. ACS)  
 
  Non-adjusted Fully adjusted 
Outcome SAP (N=3239) ACS (N=1219) HR SAP vs ACS (95% CI) 
HR SAP vs ACS (95% 
CI) p-value 
MACE, % (n) 5.96% (193/3239) 7.71% (94/1219) 0.74 (0.57-0.95) 0.72 (0.55-0.93) 0.01 
All-cause death, % (n) 1.11% (36/3239) 1.97% (24/1219) 0.57 (0.34-0.96) 0.56 (0.33-0.94) 0.03 
Cardiovascular death, % (n) 0.40% (13/3239) 0.98% (12/1219) 0.41 (0.19-0.91) 0.39 (0.18-0.89) 0.02 
Non-cardiovascular death, % 
(n) 0.71% (23/3239) 0.98% (12/1219) 0.74 (0.37-1.48) 0.71 (0.35-1.45) 0.35 
Myocardial infarction, % (n) 2.07% (67/3239) 2.54% (31/1219) 0.65 (0.41-1.03) 0.66 (0.41-1.07) 0.09 
Unplanned revascularisation, 
% (n) 4.23% (137/3239) 5.25% (64/1219) 0.86 (0.63-1.16) 0.82 (0.60-1.12) 0.63 
 
ACS denotes acute coronary syndrome; SAP, stable angina pectoris. Other abbreviations as in Table 2. 
